What are your top takeaways in Thoracic Cancers from ASCO 2022?  

1. Abst 8502 - Quality metrics and survival after lung cancer surgery: More efficient work-ups and consistently high quality resections will likely do more to improve lung cancer survival than any adjuvant or neo-adjuvant therapy we can come up with. This is low-hanging, low-cost fruit. 2. Abst 900...

1. KRYSTAL-1: This was a phase II trial of adagrasib in patients with advanced KRAS G12C NSCLC. In 112 patients who had prior immunotherapy and prior chemotherapy, the response rate was 43% with a median duration of response of 8.5 months. While sotorasib is an approved agent, adagrasib could be ano...

1. Randomized phase II trial of ramucirumab and pembrolizumab in advanced NSCLC patients who received prior ICI and chemotherapy. This was conducted through The LungMAP platform and demonstrated a 31% improvement in OS compared to standard of care therapy, including docetaxel and ramucirumab in 2/3 ...

1. Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.This validates the lack of OS benefit in giving PDL1 high patients combination therapy, and...

1. Plenary TDXD presentation: Impactful not only for breast cancer, and not even just for all HER2+ cancers, but for our understanding of ADCs. ADCs may replace cytotoxic chemotherapy for many patients. I think of them as "slightly targeted chemotherapy" -- advances in efficacy of chemo are badly ne...

1. SKYSCRAPER-02: Press release ahead of the meeting indicated the study didn't meet its endpoint. Data presented showed survival curves essentially overlapping, not even a numerical trend to favor the investigational arm of  tiragolumab added to chemoimmunotherapy as 1st line treatment for ext...